Britain's National Institute for Health and Clinical Excellence, which assesses the cost-effectiveness of new medicines that might be paid for by the country's National Health Service, reckons, for example, that abiraterone is too expensive to justify the extra months of life it brings.
ECONOMIST: Treating prostate cancer